RESUMEN
BACKGROUND: Immune cell counts in blood in severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection may be useful prognostic biomarkers of disease severity, mortality, and response to treatment. OBJECTIVES: To analyze sub-populations of lymphocytes at hospital admission in survivors and deceased from severe pneumonia due to coronavirus disease-2019 (COVID-19). METHODS: We conducted a cross-sectional study of healthcare workers confirmed with SARS-CoV-2 in convalescents (control group) and healthy controls (HC) diagnosed with severe COVID-19. Serum samples were taken at hospital admission and after recovery. Serum samples ≥ 25 days after onset of symptoms were analyzed for lymphocyte subpopulations through flow cytometry. Descriptive statistics, Kruskall-Wallis test, receiver operating characteristic curve, calculation of sensitivity, specificity, predictive values, and Kaplan-Meier analysis were performed. RESULTS: We included 337 patients: 120 HC, 127 convalescents, and 90 severe COVID-19 disease patients (50 survivors, 40 deceased). For T cells, total lymphocytes ≥ 800/µL, CD3+ ≥ 400/µL, CD4+ ≥ 180/µL, CD8+ ≥ 150/µL, B cells CD19+ ≥ 80/µL, and NK ≥ 34/µL subsets were associated with survival in severe COVID-19 disease patients. All subtypes of lymphocytes had higher concentrations in survivors than deceased, but similar between HC and convalescents. Leukocytes ≥ 10.150/µL or neutrophils ≥ 10,000/µL were associated with increased mortality. The neutrophil-to-lymphocyte ratio (NLR) ≥ 8.5 increased the probability of death in severe COVID-19 (odds ratio 11.68). CONCLUSIONS: Total lymphocytes; NLR; and levels of CD3+, CD4+, CD8+, and NK cells are useful as biomarkers of survival or mortality in severe COVID-19 disease and commonly reach normal levels in convalescents.
Asunto(s)
Linfocitos T CD4-Positivos/patología , Linfocitos T CD8-positivos/patología , COVID-19 , Linfopenia , Neutrófilos/patología , Biomarcadores/sangre , COVID-19/sangre , COVID-19/diagnóstico , COVID-19/mortalidad , COVID-19/terapia , Correlación de Datos , Estudios Transversales , Femenino , Humanos , Estimación de Kaplan-Meier , Células Asesinas Naturales/patología , Recuento de Leucocitos/métodos , Linfopenia/sangre , Linfopenia/diagnóstico , Linfopenia/etiología , Masculino , México/epidemiología , Persona de Mediana Edad , Mortalidad , Valor Predictivo de las Pruebas , Evaluación de Síntomas/métodosRESUMEN
OBJECTIVES: Tuberculosis (TB) is the leading infectious cause of death in the world. Cheaper and more accessible TB treatment monitoring methods are needed. Here, we evaluated white blood cell (WBC) absolute counts, lymphocyte, and monocyte proportions during TB treatment, and characterized their association with treatment failure. METHODS: This multicentered prospective cohort study was based in Bangladesh, Georgia, Lebanon, Madagascar, and Paraguay. Adult, non-immunocompromised patients with culture-confirmed pulmonary TB were included and followed up after two months of treatment and at the end of therapy. Blood counts were compared to treatment outcome using descriptive statistics, logistic regression, and Receiver Operating Characteristic (ROC) analyses. RESULTS: Between December 2017 and August 2020, 198 participants were enrolled, and 152 completed treatment, including 28 (18.5%) drug-resistant patients. The rate of cure at the end of treatment was 90.8% (138/152). WBC absolute counts decreased, and lymphocyte proportions increased throughout treatment. In multivariate analyses, baseline high WBC counts and low lymphocyte proportions were associated with positive sputum culture results at the end of treatment (WBC > 11,450 cells/mm3: p = 0.048; lymphocytes <16.0%: p = 0.039; WBC > 11,450 cells/mm3 and lymphocytes <16.0%: p = 0.024). CONCLUSION: High WBC counts and low lymphocyte proportions at baseline are significantly associated with the risk of TB treatment failure.
Asunto(s)
Leucocitosis/sangre , Linfocitos , Linfopenia/sangre , Monocitos , Tuberculosis Pulmonar/tratamiento farmacológico , Adulto , Bangladesh , Estudios de Cohortes , Femenino , Georgia , Humanos , Líbano , Recuento de Leucocitos , Madagascar , Masculino , Persona de Mediana Edad , Paraguay , Estudios Prospectivos , Esputo/microbiología , Insuficiencia del Tratamiento , Tuberculosis Pulmonar/sangre , Tuberculosis Pulmonar/microbiología , Adulto JovenRESUMEN
Este artículo resume las diferentes formas de presentación clínica de la enfermedad COVID-19 causada por el virus SARS-Co-2 documentadas fundamentalmente en las tres principales revisiones sistemáticas disponibles. Entre las manifestaciones clínicas de frecuente aparición se destacan la fiebre (83 %), la tos (60 %) y la fatiga (38 %), seguidas por las mialgias (29 %), el aumento de la producción del esputo (27 %) y la disnea (25 %). Entre los hallazgos de laboratorio,predominan el aumento de los valores de proteína C reactiva (69 %), la linfopenia (57 %) y el aumento de los niveles de lactato-deshidrogenasa (52 %). Respecto de las manifestaciones radiológicas, tienen especial importancia las opacificaciones en vidrio esmerilado (80 %), la neumonía bilateral (73 %) y la afectación de tres lóbulos pulmonares o más (57 %).Si bien la evidencia sintetizada tiene limitaciones, permite una aproximación actualizada a los conocimientos disponibles sobre la clínica de esta nueva enfermedad en la población adulta. (AU)
This article summarizes the different forms of clinical presentation of COVID-19, caused by the SARS-Co-2 virus, synthesizing the information collected mainly by three published systematic reviews. Frequent clinical manifestations include fever(83 %), cough (60 %), and fatigue (38 %), followed by myalgia (29 %), increased sputum production (27 %) and dyspnea(25 %). Among the laboratory findings, the most common are the increase in C-reactive protein values (69 %), lymphopenia (57 %) and the increase in lactate dehydrogenase levels (52 %).. Most remarkable radiological features include ground glass opacifications (80 %), bilateral pneumonia (73 %) and the involvement of three or more lung lobes (57 %). Although the synthesized evidence has limitations, it allows an updated approach to the available knowledge about the clinical symptoms of this new disease in the adult population. (AU)
Asunto(s)
Humanos , Adulto , Adulto Joven , Neumonía Viral/fisiopatología , Infecciones por Coronavirus/fisiopatología , Betacoronavirus/patogenicidad , Neumonía Viral/complicaciones , Neumonía Viral/etiología , Neumonía Viral/diagnóstico por imagen , Esputo , Proteína C-Reactiva/metabolismo , China , Infecciones por Coronavirus/complicaciones , Infecciones por Coronavirus/etiología , Infecciones por Coronavirus/diagnóstico por imagen , Tos/diagnóstico , Tos/fisiopatología , Tos/sangre , Disnea/diagnóstico , Disnea/fisiopatología , Disnea/sangre , Fatiga/diagnóstico , Fatiga/fisiopatología , Fatiga/sangre , Pandemias , Fiebre/diagnóstico , Fiebre/fisiopatología , Fiebre/sangre , Mialgia/diagnóstico , Mialgia/fisiopatología , Mialgia/sangre , L-Lactato Deshidrogenasa/sangre , Linfopenia/sangreRESUMEN
Elevated neutrophil-to-lymphocyte ratio (NLR) has been associated with increased mortality in patients with acute heart failure (HF) and neoplastic diseases. We investigated the association between NLR and mortality or cardiac transplantation in a retrospective cohort of 527 patients presented to the Cleveland Clinic for evaluation of advanced HF therapy options from 2007 to 2010. Patients were divided according to low, intermediate, and high tertiles of NLR and were followed longitudinally for time to all-cause mortality or heart transplantation (primary outcome). The median NLR was 3.9 (interquartile range 2.5 to 6.5). In univariate analysis, intermediate and highest tertiles of NLR had a higher risk than the lowest tertile for the primary outcome and all-causes mortality. Compared with the lowest tertile, there was no difference in the risk of heart transplantation for intermediate and high tertiles. In multivariate analysis, compared with the lowest tertile, the intermediate and high NLR tertiles remained significantly associated with the primary outcome (hazard ratio [HR] = 1.61, 95% confidence interval [CI] 1.10 to 2.37 and HR = 1.55, 95% CI 1.02 to 2.36, respectively) and all-cause mortality (HR = 1.83, 95% CI 1.07 to 3.14 and HR = 2.16, 95% CI 1.21 to 3.83, respectively). In conclusion, elevated NLR is associated with increased mortality or heart transplantation risk in patients with advanced HF.
Asunto(s)
Insuficiencia Cardíaca/sangre , Linfocitos/patología , Linfopenia/epidemiología , Neutropenia/epidemiología , Neutrófilos/patología , Medición de Riesgo/métodos , Adulto , Femenino , Estudios de Seguimiento , Insuficiencia Cardíaca/complicaciones , Insuficiencia Cardíaca/epidemiología , Humanos , Incidencia , Recuento de Leucocitos , Linfopenia/sangre , Linfopenia/etiología , Masculino , Persona de Mediana Edad , Neutropenia/sangre , Neutropenia/etiología , Ohio/epidemiología , Pronóstico , Estudios Retrospectivos , Factores de Riesgo , Tasa de Supervivencia/tendenciasRESUMEN
Narcolepsy has been studied as a possible autoimmune disease for many years, and recent findings lend more credence to this belief. Although recent and important advances have been done, no study has analyzed the role of the CD40L in patients with narcolepsy. The purpose of this study was to assess CD40L levels, CD3, TCD4, TCD8, CD19, and CD56 lymphocytes, as well as levels of tumor necrosis factor-α and interleukin-6 in narcoleptic patients. We quantified the levels of CD40L, different types of lymphocytes, and levels of tumor necrosis factor-α and interleukin-6 in narcoleptic patients and control subjects. Narcoleptic patients had lower levels of CD40L. Total lymphocytes; CD3, and TCD4 were lower than in the control group. Our findings highlight the important role of CD40L in narcolepsy.
Asunto(s)
Ligando de CD40/inmunología , Cadenas beta de HLA-DQ/análisis , Linfopenia/inmunología , Narcolepsia/inmunología , Adulto , Brasil , Complejo CD3/análisis , Complejo CD3/inmunología , Antígenos CD4/análisis , Antígenos CD4/inmunología , Ligando de CD40/análisis , Estudios de Casos y Controles , Femenino , Cadenas beta de HLA-DQ/genética , Cadenas beta de HLA-DQ/inmunología , Humanos , Interleucina-6/sangre , Interleucina-6/inmunología , Péptidos y Proteínas de Señalización Intracelular/líquido cefalorraquídeo , Recuento de Linfocitos , Linfocitos/citología , Linfocitos/inmunología , Linfopenia/sangre , Linfopenia/complicaciones , Masculino , Persona de Mediana Edad , Narcolepsia/sangre , Narcolepsia/complicaciones , Neuropéptidos/líquido cefalorraquídeo , Orexinas , Reacción en Cadena de la Polimerasa , Polisomnografía , Factor de Necrosis Tumoral alfa/sangre , Factor de Necrosis Tumoral alfa/inmunologíaRESUMEN
CD55 and CD59 are glycosylphosphatidylinositol-anchored proteins with complement inhibitory properties. CD55 inhibits the formation of C3 convertases, and CD59 prevents the terminal polymerisation of the membrane attack complex. It has been reported that SLE patients seems to have an acquired deficiency of these proteins associated with secondary autoimmune haemolytic anaemia and lymphopenia. The aim of this study was to evaluate the presence of altered CD55 and CD59 expression on peripheral blood cells from SLE patients. Flow cytometric analyses were performed on red and white blood cells from 23 SLE patients and 23 healthy controls. We observed more CD55- and CD59-lymphocytes (p=0.005 and p=0.019, respectively), and CD59-granulocytes (p=0.045) in SLE patients than in controls. These results suggest there is an altered pattern of CD55 and CD59 expression on the peripheral blood cells of SLE patients, and it may play a role in the cytopenias in these patients.
Asunto(s)
Antígenos CD55/sangre , Antígenos CD59/sangre , Lupus Eritematoso Sistémico/sangre , Adulto , Anemia Hemolítica Autoinmune/sangre , Anemia Hemolítica Autoinmune/etiología , Recuento de Células Sanguíneas , Células Sanguíneas/inmunología , Células Sanguíneas/patología , Femenino , Citometría de Flujo , Glicosilfosfatidilinositoles/sangre , Glicosilfosfatidilinositoles/inmunología , Humanos , Inmunofenotipificación , Lupus Eritematoso Sistémico/complicaciones , Lupus Eritematoso Sistémico/inmunología , Linfopenia/sangre , Linfopenia/etiología , Masculino , Persona de Mediana Edad , Adulto JovenRESUMEN
OBJECTIVE: To determine if lymphopenia is associated with clinical/immunologic manifestations, disease activity, and disease damage in systemic lupus erythematosus (SLE). METHODS: The study group comprised 591 patients with SLE participating in a multiethnic, longitudinal outcome study. Cumulative clinical/immunologic (per American College of Rheumatology criteria) and pharmacologic treatment variables were obtained at enrollment (T0) and last visit (TL). Lymphopenia (<1,500/mm3) was scored only when clinically attributable to SLE and not to medications or other causes. Lymphocyte counts were expressed in 4 categories per the Systemic Lupus Activity Measure (SLAM): normal (> or =1,500/mm3), mild (1,000-1,499/mm3), moderate (500-999/mm3), and marked (<500/mm3). Disease activity was assessed with the SLAM and the Physician's Global Assessment (PGA). Disease damage was determined with the Systemic Lupus International Collaborating Clinics Damage Index (SLICC-DI). The relationship of lymphopenia with cumulative clinical/immunologic and pharmacologic treatment variables was first examined, then the association between the SLAM, PGA, and SLICC-DI scores with different categories of lymphopenia was examined by generalized estimating equation (GEE) regression analyses. Ethnicity, age, and sex were entered into all regression models. RESULTS: At T0 and TL, lymphopenia was found to be positively associated with renal involvement, leukopenia, anti-double-stranded DNA antibodies, anti-Ro antibodies, and the use of glucocorticoids, azathioprine, and methotrexate, but was negatively associated with photosensitivity. On GEE analyses, marked lymphopenia at T0 and moderate and marked lymphopenia for all visits were independently associated with higher SLAM, PGA, and SLICC-DI scores. CONCLUSION: Lymphopenia is associated with several clinical/immunologic manifestations in SLE. Moderate and marked lymphopenia are associated with higher disease activity and damage accrual.
Asunto(s)
Lupus Eritematoso Sistémico/complicaciones , Lupus Eritematoso Sistémico/etnología , Linfopenia/complicaciones , Linfopenia/etnología , Adulto , Anticuerpos Antinucleares/inmunología , Estudios de Cohortes , ADN/inmunología , Progresión de la Enfermedad , Femenino , Humanos , Enfermedades Renales/etiología , Estudios Longitudinales , Lupus Eritematoso Sistémico/sangre , Lupus Eritematoso Sistémico/fisiopatología , Linfocitos/patología , Linfopenia/sangre , Linfopenia/fisiopatología , Masculino , Persona de Mediana Edad , Análisis Multivariante , Índice de Severidad de la Enfermedad , Estados Unidos/etnologíaRESUMEN
To evaluate lymphocyte death by neglect-apoptosis features in systemic lupus erythematosus (SLE) patients presenting with neuropsychiatric (NPSLE) involvement we studied 40 SLE patients with active disease, 20 with and 20 without neuropsychiatric manifestations, and 20 control individuals. Lymphocyte apoptosis was evaluated by means of DNA staining using flow cytometry, immediately after cell isolation and after incubation with culture medium or autologous serum. Compared with controls, NPSLE and non-NPSLE patients exhibited increased rates of neglect-apoptosis immediately after cell isolation. Only NPSLE patients exhibited an increased neglect-apoptosis rate after incubation with culture medium; however, the neglect-apoptosis rate was associated with lymphopenia in both series of patients. After lymphocyte incubation with autologous serum, only NPSLE patients exhibited a significant negative correlation between the neglect-apoptosis rate and the number of peripheral lymphocytes. The incubation of lymphocytes with autologous serum containing antiphospholipid or anti-SSA/Ro antibodies significantly increased the neglect-apoptosis in NPSLE when compared with non-NPSLE patients with a similar autoantibody profile. In conclusion, NPSLE and non-NPSLE patients shared several abnormalities in terms of lymphocyte neglect-apoptosis. Peculiar findings were observed in NPSLE patients particularly after incubation with autologous serum, such as the fact that the increased lymphocyte death by neglect-apoptosis was associated with lymphopenia and with the presence of antiphospholipid and anti-SSA/Ro antibodies.
Asunto(s)
Apoptosis/inmunología , Lupus Eritematoso Sistémico/inmunología , Vasculitis por Lupus del Sistema Nervioso Central/inmunología , Linfocitos/inmunología , Adulto , Anciano , Anticuerpos Antinucleares/sangre , Anticuerpos Antinucleares/inmunología , Anticuerpos Antifosfolípidos/sangre , Anticuerpos Antifosfolípidos/inmunología , Células Cultivadas , Humanos , Lupus Eritematoso Sistémico/sangre , Vasculitis por Lupus del Sistema Nervioso Central/sangre , Recuento de Linfocitos , Linfocitos/sangre , Linfocitos/patología , Linfopenia/sangre , Persona de Mediana EdadRESUMEN
A role for nitric oxide (NO) in the regulation of blood leukocyte numbers was examined in BALB/c mice by employing the NO synthase inhibitor NG-nitro L-arginine methyl ester (L-NAME). Treatment of animals with a single dose of 50 mg/kg body wt caused a dramatic increase in the number of circulating neutrophils and a moderate decrease in the number of circulating lymphocytes. These effects were partially reversed by the simultaneous inoculation of L-arginine (250 mg/kg body wt.) but not by D-arginine. A second NO synthase inhibitor, NG-nitro L-arginine, induced changes comparable to those elicited by L-NAME. Because catecholamines and glucocorticoids are well-known modulators of blood leukocyte counts, experiments were carried out in adrenalectomized mice. It was found that adrenalectomy did not modify the increase in the number of circulating neutrophils induced by L-NAME but completely prevented the decrease of circulating lymphocytes. Taken together, these findings support the hypothesis that NO plays an important role in the regulation of the peripheral blood number of neutrophils and lymphocytes, and that this function involves, in each case, the participation of different mechanisms.
Asunto(s)
Linfocitos/citología , Óxido Nítrico/fisiología , Animales , Arginina/análogos & derivados , Arginina/farmacología , Inhibidores Enzimáticos/farmacología , Recuento de Leucocitos/efectos de los fármacos , Linfocitos/efectos de los fármacos , Linfopenia/sangre , Linfopenia/inducido químicamente , Masculino , Ratones , Ratones Endogámicos BALB C , NG-Nitroarginina Metil Éster , Neutropenia/sangre , Neutropenia/inducido químicamente , Neutrófilos/citología , Neutrófilos/efectos de los fármacos , Óxido Nítrico/antagonistas & inhibidores , Óxido Nítrico Sintasa/antagonistas & inhibidores , Nitroarginina , EstereoisomerismoRESUMEN
O autor discorre sobre as principais funçöes dos elementos celulares sangüíneos da série branca, procurando descrever seu aumento e diminuiçäo em número nas várias moléstias, assim como o mecanismo interpretativo dessas variaçöes